F R Khuri

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer
    F R Khuri
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:2626-37. 2001
  2. ncbi request reprint The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial
    F R Khuri
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 10:823-9. 2001
  3. ncbi request reprint Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer
    F R Khuri
    Departments of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 18:2798-804. 2000
  4. ncbi request reprint Emerging therapies in non-small-cell lung cancer
    F R Khuri
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 12:739-44. 2001
  5. ncbi request reprint Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer
    S M Lippman
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 236, Houston, TX 77030 4095, USA
    J Natl Cancer Inst 93:605-18. 2001
  6. ncbi request reprint Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer
    F R Khuri
    Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 7:861-7. 2001
  7. ncbi request reprint Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma
    D M Shin
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 91:1316-23. 2001
  8. ncbi request reprint Long-term impact of smoking on lung epithelial proliferation in current and former smokers
    J J Lee
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Natl Cancer Inst 93:1081-8. 2001
  9. ncbi request reprint Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial
    D M Shin
    Departments of Thoracic Head and Neck Medical Oncology, Diagnostic Imaging, Head and Neck Surgery, Biostatistics, Radiation Oncology, and Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 19:3010-7. 2001
  10. ncbi request reprint Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses
    A S Garden
    Departments of Radiation Oncology, Thoracic Head and Neck Medical Oncology, and Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:2390-5. 1999

Detail Information

Publications23

  1. ncbi request reprint Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer
    F R Khuri
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:2626-37. 2001
    ..In this phase I/II trial, we combined bexarotene with cisplatin and vinorelbine in the treatment of patients with non-small-cell lung cancer (NSCLC)...
  2. ncbi request reprint The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial
    F R Khuri
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 10:823-9. 2001
    ..The results indicate significantly higher SPT rates in active smokers versus never smokers and significantly higher smoking-related SPT rates in active smokers versus never smokers, with intermediate rates for former smokers...
  3. ncbi request reprint Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer
    F R Khuri
    Departments of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 18:2798-804. 2000
    ..RAR-beta may suppress tumorigenicity. Therefore, we hypothesized that loss of expression of RAR-beta gene in stage I NSCLC is a prognostic factor of a poor clinical outcome...
  4. ncbi request reprint Emerging therapies in non-small-cell lung cancer
    F R Khuri
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 12:739-44. 2001
    ....
  5. ncbi request reprint Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer
    S M Lippman
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 236, Houston, TX 77030 4095, USA
    J Natl Cancer Inst 93:605-18. 2001
    ..Promising data have suggested that retinoid chemoprevention may help to control second primary tumors (SPTs), recurrence, and mortality of stage I non-small-cell lung cancer (NSCLC) patients...
  6. ncbi request reprint Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer
    F R Khuri
    Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 7:861-7. 2001
    ..Future studies of RAR-beta and COX-2 regulation in NSCLC should further the development of prevention and therapy interventions with retinoids and/or COX-2 antagonists in this patient population...
  7. ncbi request reprint Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma
    D M Shin
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 91:1316-23. 2001
    ..The trial hypothesis was that the TIC therapeutic index would be as high as that of paclitaxel, ifosfamide, and cisplatin (TIP) in this setting, but with less toxicity...
  8. ncbi request reprint Long-term impact of smoking on lung epithelial proliferation in current and former smokers
    J J Lee
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Natl Cancer Inst 93:1081-8. 2001
    ....
  9. ncbi request reprint Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial
    D M Shin
    Departments of Thoracic Head and Neck Medical Oncology, Diagnostic Imaging, Head and Neck Surgery, Biostatistics, Radiation Oncology, and Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 19:3010-7. 2001
    ..We designed the present phase II adjuvant trial to prevent recurrence or second primary tumors (SPTs) using 13-cRA, IFN-alpha, and alpha-tocopherol in locally advanced-stage head and neck cancer...
  10. ncbi request reprint Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses
    A S Garden
    Departments of Radiation Oncology, Thoracic Head and Neck Medical Oncology, and Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:2390-5. 1999
    ....
  11. ncbi request reprint A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer
    E S Kim
    Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030-4009, USA
    Lung Cancer 34:427-32. 2001
    ..The lack of encouraging results from SPI-77 use in other phase I and II studies resulted in early closure of this trial by the manufacturer...
  12. pmc A voice that wraps around the body--communication problems in the advanced stages of non-small cell lung cancer
    R J Moore
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Yale J Biol Med 74:367-82. 2001
    ..Nor have any studies evaluated the tools survivors might use to repair some of the damage caused by living with this disease...
  13. ncbi request reprint Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
    J E Tseng
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 92:2364-73. 2001
    ..Potentially, future evaluations of thalidomide may be performed in combination with other antiangiogenic or cytotoxic agents in patients with earlier stage disease or in patients with minimal residual disease...
  14. ncbi request reprint Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer
    D M Shin
    Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 7:1204-13. 2001
    ....
  15. ncbi request reprint Phase I trial of oral green tea extract in adult patients with solid tumors
    K M Pisters
    Department of Thoracic Head and Neck Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:1830-8. 2001
    ..This trial was designed to determine the maximum-tolerated dose, toxicity, and pharmacology of oral green tea extract (GTE) once daily or three times daily...
  16. ncbi request reprint Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers
    F R Khuri
    The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 10:311-8. 2001
    ..The modulation of PCNA by 13-cRA in patients who quit smoking suggests a potentially important role for regulating this proliferation marker in retinoid chemoprevention studies of former smokers...
  17. ncbi request reprint Epidermal growth factor receptor biology (IMC-C225)
    E S Kim
    Department of Thoracic Head and Neck Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Curr Opin Oncol 13:506-13. 2001
    ..Ultimately, IMC-C225 may prove to become a valuable contributor in the treatment of cancer. This report will focus on IMC-C225, a novel monoclonal antibody that targets the EGFR...
  18. ncbi request reprint Racial disparity in survival of patients with squamous cell carcinoma of the oral cavity and pharynx
    R J Moore
    Department of Epidemiology, Box 189, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Ethn Health 6:165-77. 2001
    ..This study was designed to determine if race and age are independent prognostic factors for survival in patients treated for squamous cell carcinoma of the oral cavity and pharynx...
  19. ncbi request reprint A qualitative study of head and neck cancer
    R J Moore
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Support Care Cancer 12:338-46. 2004
    ..This qualitative study provides a perspective as to why such under-reporting occurs, thereby potentially enhancing clinician-patient communication and the QOL of SCCHN patients who present with curable disease...
  20. ncbi request reprint Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
    J Nemunaitis
    US Oncology, Baylor University Medical Center, Dallas, TX, USA
    J Clin Oncol 18:609-22. 2000
    ..To determine the safety and tolerability of adenovirus-mediated p53 (Adp53) gene transfer in sequence with cisplatin when given by intratumor injection in patients with non-small-cell lung cancer (NSCLC)...
  21. ncbi request reprint Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature
    K B Kim
    Department of Melanoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Pharm Ther 31:401-6. 2006
    ....
  22. ncbi request reprint Communicating suffering in primary stage head and neck cancer
    R J Moore
    Departments of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Eur J Cancer Care (Engl) 13:53-64. 2004
    ..This study provides a perspective on why this under-reporting occurs, thereby potentially enhancing clinician-patient communication and the QOL of SCCHN patients who present with curable disease...
  23. ncbi request reprint Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer
    J V Heymach
    Dana Farber Cancer Institute and Massachusetts General Hospital, Boston, MA 02115, USA
    Ann Oncol 15:1187-93. 2004
    ..This multicenter phase II study was conducted to determine the efficacy, tolerability and pharmacokinetics of R115777 in patients with relapsed small-cell lung cancer (SCLC)...